ZYDUS CADILA GETS USFDA APPROVAL TO MARKET DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION

Highlights

• Zydus Cadila in the statement issued on Friday said that it has received final approval from the USFDA to market Doxorubicin Hydrochloride Liposome injection in the strengths of 20 mg/10 mL (2mg/mL) and 50 mg/25 mL (2mg/mL) single-dose vials

• Zydus Casual said this is its first approval for a complex injectable which has been developed in-house and will be manufactured at the group’s facility